Abstract
Previously we have shown that synergism between inositol-1,4,5-trisphoshate (IP3) and diacylglycerol (DAG) mediates activation of TRPC6-like channel activity by noradrenaline (NA, Albert & Large, 2003) in rabbit portal vein myocytes. Moreover, a recent study showed that endogenous phosphatidylinositol-4,5-bisphosphate (PIP2) produced a marked inhibitory action on TRPC6 activity in mesenteric artery myocytes (Albert et al, 2008). In the present work we investigated interactions between DAG, IP3 and PIP2 in regulating TRPC6-like activity in portal vein myocytes using patch clamp and immunoprecipitation methods. In inside-out and cell-attached patches, bath application of respectively 10 μM IP3 and the cell-permeable IP3 analogue, 10 μM 6-IP3, both potentiated OAG-induced TRPC6-like channel activity by 3-fold but had no effect when applied on their own. In inside-out patches, pre-treatment with 20 μM wortmannin, to deplete endogenous PIP2 levels, increased OAG-evoked channel activity by 75-fold compared to control patches. Moreover, anti-PIP2 antibodies activated TRPC6-like activity in quiescent inside-out patches. In wortmannin-treated inside-out patches, 10 μM diC8-PIP2 inhibited OAG evoked channel activity (IC50 = 0.74 μM) which was rescued by over 50 % by co-application of 10 μM IP3. Anti-TRPC6 and anti-TRPC7 antibodies inhibited TRPC6-like activity induced by NA by over 80%, but channel activity was unaffected by other TRPC antibodies. Co-immunoprecipitation studies showed association between TRPC6 and TRPC7 proteins and that both these channel proteins interacted with PIP2. Pretreated with 6-IP3, reduced association between PIP2 and TRPC7 but not TRPC6, whereas OAG reduced PIP2 interactions with TRPC6 but not TRPC7. These results indicate that endogenous PIP2 has a pronounced inhibitory action on TRPC6/TRPC7 heteromeric channels in portal vein myocytes. Moreover channel activation by DAG requires both this triglyceride and IP3 to remove associations between PIP2 and these channel proteins.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.